Aberdeen Group’s Arcellx ACLX Stock Holding History

Aberdeen Group’s Portfolio ACLX Stock Details ACLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-60,364	Closed	-$3.94M	–	933
2025 Q4	$3.94M	Buy	+60,364	New	+$4.82M	0.01%	720
2024 Q4	–	Sell	-50,796	Closed	-$4.24M	–	931
2024 Q3	$4.24M	Buy	+50,796	New	+$3.38M	0.01%	677

Other funds holding ACLX

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Aberdeen Group's ACLX Position: Q1 2026 in Review

Aberdeen Group sold out of Arcellx (ACLX) in Q1 2026, closing a stake of 60,364 shares — an estimated $3.94M sold.

Aberdeen Group first reported a position in ACLX in Q3 2024 and held it in 2 quarters. The position peaked at $4.24M in Q3 2024. 239 funds tracked by Wall St. Rank hold ACLX as of Q1 2026.

Aberdeen Group reported no remaining Arcellx position as of Q1 2026 after selling out during the quarter.
Aberdeen Group sold 60,364 Arcellx shares in Q1 2026, an estimated $3.94M.
Aberdeen Group first reported a position in Arcellx in Q3 2024 and held it in 2 quarters.
Aberdeen Group's Arcellx position peaked at $4.24M in Q3 2024.
239 funds tracked by Wall St. Rank held Arcellx as of Q1 2026.

Based on Aberdeen Group's 13F filing for Q1 2026, filed 29 Apr 2026.